Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Seasonal Allergy and Seasonal Decrements in Athletic Performance

Hirsh D. Komarow, MD\textsuperscript{a,b,*}, Teodor T. Postolache, MD\textsuperscript{b,c}

\textsuperscript{a}Laboratory of Allergic Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
\textsuperscript{b}Department of Psychiatry, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
\textsuperscript{c}Institute for Sports Chronobiology, 2423 Pennsylvania Avenue, NW, Washington, DC 20037, USA

Allergic diseases are among the most common chronic diseases and have been increasing worldwide over the past several decades for reasons that are still not clearly understood\cite{1–6}. There has been considerable research elucidating the impact that allergic disease has on athletic performance. Athletes who have allergic disease can benefit from the tremendous progress that has been made in understanding the pathophysiologic basis of their disease. Accessing the host of international climatic and seasonal pollen reports available can enable athletes to be better prepared for training and performance. Additionally, athletes can benefit from an evolving repertoire of therapeutic modalities for allergic diseases that conform to current antidoping codes (www.wada-ama.org).

Pathophysiology of allergic disease

Atopic diseases such as asthma, allergic rhinitis, urticaria, and anaphylaxis are characterized by hypersensitivity to a particular allergen, resulting in secretion of specific immunoglobulin E (IgE) antibodies and acute, recurrent, or chronic inflammation. Certain individuals with an atopic predisposition synthesize IgE
antibodies on initial exposure to allergen. IgE binding to mast cells and basophils sets the stage for the allergic response. On re-exposure, allergen cross-links IgE on cell surfaces, which causes the release of a host of inflammatory mediators. Early response mediators include granule mediators (eg, histamine, tryptase) and lipid mediators (eg, leukotrienes, prostaglandins). Cytokines such as tumor necrosis factor-alpha (TNF-α), interleukins, and chemokines (IL-8, MCP-1 and MIP-1α) are produced minutes to hours later (Fig. 1) [7,8]. The type of allergen, the degree and length of exposure, and the atopic tendency of the individual determine the manifestation of symptoms.

Sources of allergens include the environment (eg, tree, grass and weed pollen, dust, mold), foods, drugs, and stinging insects. Aeroallergens are further subdivided into seasonal aeroallergens, like tree, grass and weed pollen, and nonseasonal aeroallergens like mold and dust [9].

**Pollen counts**

The concentration of pollen in the atmosphere, which correlates with allergic manifestations, is reported and disseminated at multiple centers internationally. In the United States and Canada, a useful resource is The National Allergy Bureau, which provides pollen and mold counts from approximately 75 counting stations (www.aaaai.org/nab/).

---

**Fig. 1. Mediators of mast cells and basophils.** TNF, tumor necrosis factor; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; MCP, monocyte chemotactic protein; MIP, monocyte inflammatory protein.
Manifestations of allergy

Physical manifestation of allergy is often debilitating. In the lung there may be bronchoconstriction or asthma; in the nose, rhinitis; in the skin, urticaria; in the eyes, conjunctivitis. Systemic manifestations of allergy characterize anaphylaxis, which may be life threatening and require immediate medical attention. Anaphylaxis that occurs in conjunction with exercise, termed exercise-induced anaphylaxis, has been reported in certain individuals [10]. In addition to the inflammatory response, allergic disease manifestations have been associated with fatigue [11], depression [12], and decrements in cognition [13]. In fact, epidemiologic evidence suggests that seasonality of even extreme behavioral manifestation, such as suicide, may be associated with allergy [14] or with exposure to seasonal allergens, specifically tree pollen [15].

Diagnosis of allergy

In addition to the clinical manifestations of an allergic disorder, in vivo and laboratory-based testing for allergen sensitivity is used to strengthen the diagnosis of allergic disease. Skin-prick and intradermal testing provide a rapid and functional measure of IgE-mediated hypersensitivity in the skin with a resultant wheal and flare response that occurs within 15 minutes of allergen contact. In situations of decreased skin response from treatment with antihistamines, increased skin sensitivity from dermatographism, or logistical constrains, athletes may opt for the radioallergosorbent test (RAST), which detects specific IgE antibodies in serum with comparable sensitivity and specificity to skin-prick testing [16].

Seasonal effects of allergy on athletes

Environmental exposures

Athletes are particularly vulnerable to the effects of the environment, as many athletic activities—whether they are for leisure, training, or competition—occur outdoors. When athletes train and compete, often for long durations of time, they make intimate contact with the outdoor elements that are comprised of a host of topographical, seasonal, and climatic components. Exposure to the various elements is magnified by increased ventilation (up to 200 L/min during exercise), which intensifies the contact between the respiratory system and environment, and by inhalation of poor quality and cold air, which often affects those who train year-round in temperate climates [17,18]. During the winter months, cold air inhalation during exercise exacerbates exercise-induced asthma in people.
with asthma [19]. Track and field athletes have extensive exposure to various seasonal pollen allergens during the spring (trees), summer (grass), and early fall (ragweed) [20]. Susceptible athletes may develop conjunctival inflammation, rhinitis, or bronchial inflammation as a consequence of these environmental conditions.

**Allergies and Olympic athletes**

Based on a 15-year database of aeroallergen records, an in-depth study reported the predicted aeroallergen counts that would be observed in association with the 2004 Olympic games in Athens, Greece. The study predicted that peak pollen concentrations would be observed during training in March and May, and high levels of goosefoot, mugwort, Alternaria, and Cladisporum spores would be observed in August and September during the Olympic games [21], thus highlighting the need for preparation, testing, and therapy.

An earlier survey of allergic disease in elite athletes reported that 20% of the 1984 Australian Olympic team had allergic disorders based on clinical evaluation (not including skin testing or RAST) [22]. Of 214 Australian Olympic athletes studied during the 2000 Sydney Olympics, which took place during the period of high tree pollen (over 5000 grains per cm$^2$M), a high prevalence of perennial and seasonal allergic disease was reported. Within that group, 56% reported a history of allergic rhinoconjunctivitis, 41% were symptomatic with a positive skin test to a potential allergen, 29% were diagnosed with seasonal allergic rhinoconjunctivitis based on history and skin testing, and 21% suffered from asthma [23]. Before the 2004 Olympics in Athens, Greece, information regarding circulating aeroallergens in neighboring cities was published to attempt to minimize the allergy symptoms and help athletes achieve peak performance. Understandably, the incidence of adverse responses to seasonal allergens is common amongst athletes. Although athletes with allergic diseases have successfully won many Olympic medals, the detrimental contribution of pollutants, allergens, or other environmental factors has occasionally produced severe exacerbations of allergic conditions, warranting medical attention and causing suboptimal performance.

Seasonal exposures to infectious agents may also induce seasonal decrements in athletic performance. Viral infections reviewed in Nelson et al [24], such as influenza, reovirus, and respiratory syncytial virus, manifest a seasonal peak in winter and early, cause significant morbidity, may trigger bronchial hyperreactivity, and may result in secondary bacterial infections such as sinus or bronchial infections (Table 1).

Several studies have characterized the relationship between viral infection, which is primarily a T-helper type 1 (Th1) response, and enhancement of allergic disease, which is a T-helper type 2 (Th2) response. Viral infections like influenza A may trigger allergic asthma by interfering with tolerance to aeroallergens [25], inducing a concomitant Th1 response [26], and causing recruitment of Th2 cells.
into the lung [27]. In some people, seasonal allergy and mood vulnerability to inflammation may interact, and people with allergies may experience more post-flu mood worsening than those without allergies [28].

Allergic rhinitis

Allergic rhinitis in athletes

Often the initial contact of pollen and other airborne components is with nasal mucosal and eyes. Studies have shown that allergic rhinoconjunctivitis is under-recognized and certainly undertreated in elite athletes [18]. Helenius et al [29] reported the results of a survey of 49 athletes competing in summer events. The diagnosis of allergic rhinoconjunctivitis was more common among athletes than in a control group of nonathletes ($P = .037$). Helbling et al [30] surveyed 2961 Swiss athletes who participated in 68 sports. Of the 79% who responded to the questionnaire, 16.8% indicated they suffered from hay fever and 59% reported that they needed medication during the pollen season. Individuals who have allergic rhinitis also often have increased bronchial hyperresponsiveness [31,32].

Pathophysiology and presentation

Allergic rhinitis (AR) is characterized by nasal mucosa edema as a result of IgE-mediated release of early- and late-phase mediators and Th2 cytokines, which promotes the infiltration of mucosa with inflammatory cells such as eosinophils, neutrophils, basophils, T cells, and macrophages [2,33,34]. AR is characterized by nasal congestion, rhinorrhea, sneezing, itching of the nose, or postnasal drainage and is often associated with allergic conjunctivitis manifested by ocular itch, tearing, redness, and sometimes swelling and photophobia. These and other signs and symptoms of AR are listed in Box 1. Allergic, irritant,

| Infection                     | Peak prevalence                        |
|-------------------------------|----------------------------------------|
| Malaria                       | Winter–early spring                    |
| Leishmaniasis                 | Winter–early spring                    |
| Influenza                     | Winter–early spring                    |
| Human reovirus                | Winter                                 |
| Coronavirus                   | Winter–early spring                    |
| Respiratory syncytial virus   | Winter–early spring, summer            |

Adapted from Nelson RJ, Demas GE, Klein SL, et al. Seasonal patterns of stress, immune function, and disease. 1st edition. Cambridge, MA: Cambridge University Press; 2002.
infectious, hormonal, occupational, and other factors are causative agents in nasal mucosal edema [35]. Peak presentations of allergic rhinoconjunctivitis occur between 10 to 25 years, which includes the age range of most elite athletes [3].

Allergic rhinitis and athletic performance

Although exercise may increase nasal airway patency, likely by way of increased sympathetic nerve discharge [36], there are several reasons why AR may interfere with athletic performance. Rhinitis often causes changes in sleep patterns because of nasal obstruction, rhinorrhea, and sinus pressure that add to tiredness and fatigue and impair athletic performance [18]. Additionally, short bursts of sprinting require nasal breathing for optimal performance [36], implicating nasal obstruction as a deleterious factor in performance. AR has been associated with alteration in central nervous system (CNS) function, which may significantly affect the athlete’s ability to perform. Using a standardized computer-based battery of cognitive processing tests, subjects who have AR experienced decrements in reaction time, attention, and vigilance when exposed to pollen [13]. Others associated AR with increased fatigue [11], depression [11,37], and anxiety in women [38], which all pose a potential hindrance to performance.

The mechanism by which seasonal environmental exposures may affect these cognitive and emotional parameters has not been elucidated. Reichenberg et al [39] has shown activation of the innate immune response in humans by low-dose endotoxin exposure and subsequent release of pro-inflammatory cytokines (eg, IL-1, IL-6, TNF-α), some of which are also released by IgE-mediated responses in the nasal mucosa (see Fig. 1) [40,41]. The exposure to endotoxins and secretion of cytokines induced depressive symptoms, anxiety, and cognitive impairment in the absence of constitutional symptoms (eg, decreased energy, anorexia, drowsiness) [39,42]. Circulating cytokines may also induce activation of the HPA-axis [43], and elevation of corticotrophin-releasing factor (CRF)}
and cortisol have been shown to contribute to major affective illness [44]. Furthermore, cytokines in the respiratory tract may stimulate specific receptors present in the vagus nerve and affect brain function through this pathway [45]. As such, cytokine release could contribute to decrements in cognition and to the onset or exacerbation of depression or anxiety, thus having detrimental effects on athletic performance.

Management of allergic rhinitis

Prevention

Athletes must prepare themselves for the various climatic conditions they will encounter in their training locale and the competition destinations. Knowledge of the temperature, humidity, sunlight, altitude, season, and type and concentration of pollen they will be exposed to can help athletes achieve peak performance through the use of prophylactic measures [21].

Nonpharmacologic therapy

Various nonpharmacologic therapies have been effective under certain conditions. For the treatment of AR, saline nasal irrigation is a safe and effective method of cleansing the nasal mucosa of allergens, and improving nasosinus disease [46]. External nasal dilators have been used by athletes [47] to increase nasal valve area, which is the narrowest area in the nasal canal [46,48], and to significantly decrease submaximal exercise-perceived exertion, heart rate, ventilation, and volume of oxygen use [47].

Pharmacologic treatment and doping concerns

Beginning with the earliest Olympic games, athletes have enhanced athletic performance through the use of foreign substances. In 1967, the International Olympic Commission developed a list of prohibited methods and substances to protect the health of, and foster equality for, all competing athletes [49]. In the realm of allergic diseases, these restrictions have generated significant challenges. For example, the overall Olympic champion in women’s gymnastics at the 2000 Olympics was disqualified and her gold medal withdrawn because she used a medication for AR which contained pseudoephedrine, allegedly without the intent of doping. Pseudoephedrine is no longer on the Prohibited List (Table 2). In 1972, the winner of the 400-meter men’s Freestyle was disqualified because significant levels of the banned drug ephedrine were detected in his post-race urinalysis. The swimmer had used a combination ephedrine/theophyl-
| Drug                     | Mode of action | Use                                      | Comments                                                                                                                                   | WADA status<sup>a</sup> |
|--------------------------|----------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| **Antihistamines**       |                |                                          |                                                                                                                                           |                          |
| Oral first-generation    | Oral           | Allergic rhinitis and conjunctivitis, urticaria, allergic asthma | First-line therapy for mild to moderate symptoms                                                                                          | Not prohibited           |
| Oral second-generation   | Oral, Intranasal | Treatment of many allergic diseases: allergic rhinitis and conjunctivitis, asthma, urticaria, and atopic dermatitis | Potent antiinflammatory intranasal — first-line therapy for moderate to severe symptoms of rhinitis oral — severe exacerbations of asthma, urticaria | Systemic<sup>b</sup> uses are prohibited<sup>c</sup>; inhaled and intranasal only require abbreviated TUE<sup>d</sup>; topical are not prohibited |
| Topical (optical)        | Intranasal     |                                          |                                                                                                                                           |                          |
| **Corticosteroids**      |                |                                          |                                                                                                                                           |                          |
| Oral                     | Oral, Inhaled, Intranasal, Topical (skin) |                                          |                                                                                                                                           |                          |
| **Decongestants**        |                |                                          |                                                                                                                                           |                          |
| Oral                     | Oral, Intranasal | Causes nasal vasoconstriction | Reduces nasal congestion May cause insomnia, loss of appetite, and nervousness Intranasal may cause rebound nasal congestion (rhinitis medicamentosa) | Ephedrine is prohibited<sup>e</sup>, phenylephrine, phenylpropanolamine, pseudoephedrine, and synephrine are on monitoring list<sup>f</sup> |
| **Cromolyn/nedocromil sodium** |                |                                          |                                                                                                                                           | Not prohibited           |
| Oral                     | Oral, Inhaled, Intranasal | Inhibits degranulation | Asthma, allergic rhinitis Nonsteroidal antiinflammatory Minimal adverse effects Requires multiple daily dosing |                          |
| Therapeutic Class             | Mechanism of Action                                                                 | Disease(s)                                         | Effectiveness/Role                                                                                         | Prohibition Notes |
|------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------|
| Anticholinergic Muscarinic   | Role in acute bronchospasm                                                         | Asthma, rhinitis                                   | Effectively reduce rhinorrhea                                                                             | Not prohibited   |
| Inhaled antagonist           |                                                                                     |                                                    | Role in acute bronchospasm                                                                             |                  |
| Intranasal                   |                                                                                     |                                                    |                                                                                                           |                  |
| Leukotriene inhibitors       | Inhibit phospholipid metabolism                                                     | Asthma                                            | Nonsteroidal antiinflammatory                                                                          | Not prohibited   |
| Oral                         |                                                                                     |                                                    | Very effective in preventing EIA                                                                        |                  |
|                             | Inhaled                                                                             |                                                    | Steroid sparing controller                                                                             |                  |
|                             |-role in acute bronchospasm                                                          |                                                    |                                                                                                           |                  |
|                             | Inhaled                                                                             |                                                    |                                                                                                           |                  |
|                             | Inhaled                                                                             |                                                    |                                                                                                           |                  |
| Allergen immunotherapy       | Th2 response suppression                                                             | Allergic rhinitis and conjunctivitis, asthma      | Very effective for allergic rhinitis                                                                      | Not prohibited   |
|                             | Th1 response stimulated                                                              |                                                    |                                                                                                           |                  |
|                             | Reduces serum IgE                                                                   |                                                    |                                                                                                           |                  |
|                             |                                                                                     |                                                    |                                                                                                           |                  |
| Anti-IgE antibody            | Reduces serum IgE                                                                   | Severe asthma, possibly allergic rhinitis          | Approved for severe asthma                                                                             | Not prohibited   |
| IM injection                 |                                                                                     |                                                    | Requires multiple IM injections                                                                        |                  |
|                             |                                                                                     |                                                    | Expensive                                                                                                 |                  |
| β2 agonist                   | Bind β2-adrenergic receptor, ↑ cAMP, relaxes bronchial smooth muscle                 | Asthma                                            | First-line therapy in preventing EIA                                                                      | Prohibited in general, some formulations with specific clinical indications require only an abbreviated TUE<sup>g</sup> |
| Inhaled                      |                                                                                     |                                                    |                                                                                                           |                  |
| Short-acting                 |                                                                                     |                                                    |                                                                                                           |                  |
| Long-acting                  |                                                                                     |                                                    |                                                                                                           |                  |
| Theophylline                 | Inhibits phosphodiesterase, causing bronchodilation                                 | Asthma                                            | Long-term controller                                                                                     | Not prohibited   |
| Oral                         |                                                                                     |                                                    | Required serum level monitoring                                                                        |                  |
| Inhaled                      |                                                                                     |                                                    |                                                                                                           |                  |
| Epinephrine                  | α- and β-adrenergic agonist                                                         | Anaphylaxis                                       | Universally recommended drug of choice for acute anaphylaxis                                             | During competition requires a TUE |
|                             |                                                                                     |                                                    | Adult dose: SQ or IM, 0.2–0.5 ml of 1/1000 (wt/vol) dilution                                              |                  |
|                             |                                                                                     |                                                    |                                                                                                           |                  |

**Abbreviations:** cAMP, cyclic adenosine monophosphate; EIA, exercise-induced asthma; IM, intramuscularly; SQ, subcutaneously; TUE, therapeutic use exemption.

<sup>a</sup> Based on the WADA 2005 Prohibited List International Standard, see [www.wada.com](http://www.wada.com) for current updated information.

<sup>b</sup> Orally, rectally, IV, or IM.

<sup>c</sup> In competition only. Any substance or method that is on the Prohibited List must be granted a Therapeutic Use Exemption (TUE) for use.

<sup>d</sup> Nonsystemic routes require the completion of an abbreviated TUE application. Dermatological preparations are not prohibited.

<sup>e</sup> Prohibited when its concentration in urine is >5 mcg/mL.

<sup>f</sup> These stimulants are no longer on the Prohibited List, but are on the 2005 monitoring program “in order to detect patterns of misuse in sports.”

<sup>g</sup> All β2-agonists including their D- and L-isomers are currently (2005) prohibited in and out of competition and require a TUE for use. Formoterol, salbutamol, salmeterol, and terbutaline are permitted by inhalation to prevent and or/treat asthma and exercise-induced asthma/bronchoconstriction, with the completion of abbreviated TUE application.
line preparation for the prerace treatment of his asthma [22]. These examples highlight the importance for athletes, coaches, and team physicians to understand the potential that a particular medication, apparently innocuous, may contain or be contaminated by a particular banned substance. To establish a universal internationally standardized Olympic antidoping code, the World Anti-Doping Agency (WADA) was established in 1999. The WADA disseminates current information on substances prohibited for use by competitive athletes. WADA maintains and updates the World Anti-Doping Code Prohibited List, which includes substances that are prohibited only during competition, others that are always prohibited, and others that are on the monitoring list (see Table 2). More and current updated information regarding antidoping rules, regulations, and prohibited substance listings can be found at www.wada-ama.org.

Pharmacologic therapies

Oral decongestants, such as pseudoephedrine and phenylpropanolamine, are effective in reducing nasal congestion from rhinitis, although they can cause insomnia, loss of appetite, and excessive nervousness [3,50]. These decongestants are no longer on the Prohibited List, but have been placed on the 2005 Monitoring Program to detect patterns of misuse in sports (see Table 2). Topical α-adrenergic nasal decongestants are commonly used, but may cause rhinitis medicamentosa, the syndrome of rebound nasal congestion, when overused [3]. Antihistamines are commonly used, have long been standard therapy for seasonal and perennial AR, and are effective in relieving symptoms of itching, sneezing and rhinorrhea, and allergic conjunctivitis [6,51]. The older first-generation antihistamines are significantly limited by their sedative and anticholinergic adverse effects and may compromise important psychomotor skills (eg, reaction time, visual discrimination) [52], and therefore should be avoided. The newer second-generation antihistamines are preferred because of their longer duration of action and minimal, if any, CNS adverse effects [53,54]. Intranasal steroids are likely the most effective therapy for AR and allergic conjunctivitis. Their efficacy is maximized with continuous use [53], but there are also proven as-need benefits [55]. They have the benefit over antihistamines of down-regulating numerous steps in the inflammatory process, including reducing the release of cytokines and chemokines [56]. Their use in Olympic athletes requires the application for an abbreviated therapeutic use exemption (TUE). Several studies have shown concurrent reduction with use of intranasal corticosteroids in bronchial hyperresponsiveness [5]. Leukotriene modifiers have confirmed benefit in allergic rhinitis comparable to antihistamines [57]. Other effective intranasal agents include intranasal antihistamines, ipratropium bromide, and cromolyn sodium [3]. To date, there have been no published reports of immunotherapy specifically targeting elite athletes [18]. However, allergen immunotherapy significantly decreases the severity of AR, reduces the requirement for pharmacotherapy, and improves quality of life [53].
Asthma

Asthma in athletes

Asthma is characterized by variable airflow obstruction, bronchial hyper-responsiveness, and airway inflammation. Respiratory viral infections (most common), allergens, irritants, drugs, climatic conditions, exercise, and other stimuli can induce asthmatic exacerbations. In a survey of 214 athletes representing 12 Olympic sports, 21% reported having experienced asthma [23]. The reason for the higher prevalence of asthma among athletes is because of their exposure to various climatic conditions (eg, cold in winter), pollen content (eg, grass, weed, trees), and various pathophysiologic changes that occur during exercise that may promote bronchial hyperresponsiveness [17,19,58–63]. When strenuous exercise results in resistance to airflow, the phenomenon is called exercise-induced bronchospasm or exercise-induced asthma (EIA) [19].

Exercise-induced asthma

Pathogenesis and presentation

Various factors have been described in the development of EIA. The generally accepted pathogenesis of EIA involves the loss of heat and water from airway mucosa [59,64–66]. During exercise and increased respiratory rate, large volumes of dry, cold air reduce airway cooling as it travels along the tracheobronchial tree, which may cause bronchial constriction through a reflex stimulation of airway receptors. This response may lead to changes in mucosal osmolarity and promote mast cell degranulation, consequently furthering bronchoconstriction [67]. Rapid airway rewarming after exercise may cause vascular congestion, increased permeability, and edema, leading to obstruction [19,68].

EIA symptoms of chest tightness, wheezing, and shortness of breath generally follow a brief period of bronchodilation that occurs at initiation of exercise. Bronchoconstriction peaks 8 to 15 minutes after exercise and resolves in about 60 minutes. A refractory period of up to 3 hours after recovery, during which time repeat exercise causes less bronchospasm, has been observed [68]. Although EIA generally commences following the cessation of physical exertion, it may also appear during sustained activity [69].

Seasonal consideration in exercise-induced asthma

Track and field athletes are extensively exposed to seasonal allergens. When the rate of breathing exceeds 30 L/min, there is a shift from nose breathing to combined mouth and nasal breathing, thereby increasing deposition of airborne allergens and other inhaled particles into the lower airway [20]. Asthmatic subjects who are allergic to birch pollen were shown to have aggravated EIA
responses during the pollen season when compared with the response of asthmatic individuals who are not allergic to birch pollen [63].

**Challenges in the diagnosis of exercise-induced asthma**

In has been reported that 40% to 90% of asthmatics have EIA [61,67,70–72]. Before the 1984 Summer Olympics, 67 of 597 (11%) athletes screened for performance experienced symptoms of EIA, yet only 26% of these athletes had a history of asthma [60]. However, 42 of 67 reported symptoms of asthma during strenuous exercise, thus emphasizing the importance of screening for EIA in well-conditioned individuals who appear to be in excellent health [73].

EIA is a common and often unrecognized problem among school-age participants in sports [74]. In a cohort of 256 adolescent athletes, 9.4% were diagnosed with EIA. Yet screening for EIA through physical examination and history did not accurately predict it and would have detected only about half of the children who were diagnosed as having EIA using spirometry [75]. Furthermore, 9% of individuals in the general population who have EIA have no history of asthma.

**Management of asthma**

**Prophylaxis**

Detailed prior knowledge of environmental exposures can help prevent or minimize exacerbation. Once a pattern of symptoms has been established, prophylaxis is the key to therapy in patients who have EIA. Physical warm-up can reduce EIA. Continuous, low-intensity warm-up is more effective than interval warm-up in preventing EIA in athletes [76]. In certain cold conditions, such as those experienced by cross-country skiers, breathing filters are being used [67]. Although there is no clear evidence that physical conditioning decreases EIA or improves pulmonary function, it does delay the symptoms of EIA from reaching threshold [77].

**Pharmacologic therapy**

Long-term and more effective control is gained with pharmacologic intervention. The most common and effective prophylactic therapies used before exercise are $\beta_2$ agonists, cromolyn, and nedocromil (see Table 2) [78–80]. Inhaled corticosteroids may be helpful in reducing bronchial hyperresponsiveness when used for their long-term antiinflammatory effects. Theophylline preparations and anticholinergics are used as tertiary agents when other agents are proven ineffective. However, the requirement for blood-level monitoring of a narrow therapeutic window makes theophylline a less desirable alternative agent for athletes [61]. Short-acting $\beta_2$ agonists are considered first-line therapy and
provide protection in 80% to 90% of subjects with minimal adverse effects [81,82]. Long-acting \( \beta_2 \) agonists can prevent bronchial obstruction for 10 to 12 hours [83] and provide athlete with a full day of protection. Formoterol, salbutamol, salmeterol, and terbutaline are permitted by inhalation with the completion of an abbreviated TUE, but all other \( \beta_2 \) agonists, including their D- and L-isomers are prohibited in and out of competition, according to the 2005 Prohibited List (see Table 2). Regular use of \( \beta_2 \) agonists without antiinflammatory treatment may increase airway responsiveness to irritants and foster allergen-induced late bronchoconstriction and airway inflammation [84].

Given the central role of IgE in the pathogenesis of allergic disease, inhibiting IgE responses through the use of anti-IgE antibodies would decrease its sensitizing effects on mast cells and basophils. Several studies indicate that anti-IgE therapy is effective in the treatment of asthma and allergic rhinitis [85–88]. However, the implications for athletes are unknown.

In conclusion, evidence supports that seasonal allergy confers a seasonal vulnerability for performance decrements in competition and training. Specific interventions that prevent and directly address the allergic symptomatology, tailored to athletes’ individual needs in specific circumstances, could prevent seasonal decompensation in performance or restore functioning to baseline levels.

Acknowledgments

We would like to thank Dr. Dean D. Metcalfe for his suggestions regarding the organization of this article.

References

[1] Annesi-Maesano I. Epidemiological evidence of the occurrence of rhinitis and sinusitis in asthmatics. Allergy 1999;54(Suppl 57):S7–13.
[2] Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478–518.
[3] International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy 1994;49(Suppl 19):S1–34.
[4] Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351(9111):1225–32.
[5] Casale TB, Amin BV. Allergic rhinitis/asthma interrelationships. Clin Rev Allergy Immunol 2001;21(1):27–49.
[6] Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med 2002;113(Suppl 9A):S17–24.
[7] Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol 2003;111(1):24–32 [Quiz Review 33].
[8] Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004;257:65–74.
[9] Solomon WR. Airborne pollen: a brief life. J Allergy Clin Immunol 2002;109(6):895–900.
[10] Castells MC, Horan RF, Sheffer AL. Exercise-induced anaphylaxis. Curr Allergy Asthma Rep 2003;3(1):15–21.
[11] Marshall PS, O’Hara C, Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002;64(4):684–91.
[12] Timonen M, Jokelainen J, Herva A, et al. Presence of atopy in first-degree relatives as a predictor of a female proband’s depression: results from the Northern Finland 1966 Birth Cohort. J Allergy Clin Immunol 2003;111(6):1249–54.
[13] Wilken JA, Berkowitz R, Kane R. Decrement in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002;89(4):372–80.
[14] Timonen M, Viiko L, Hakko H, et al. Is seasonality of suicides stronger in victims with hospital-treated atopic disorders? Psychiatry Res 2004;126(2):167–75.
[15] Postolache TT, Stiller JW, Herrell R, et al. Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry, in press.
[16] Hamilton RG, Adkinson Jr NF. 23. Clinical laboratory assessment of IgE-dependent hypersensitivity. J Allergy Clin Immunol 2003;111(Suppl 2):S687–701.
[17] Helenius IJ, Tikkanen HO, Haataela T. Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen. Br J Sports Med 1998;32(2):125–9.
[18] Katelaris CH, Carrozzi FM, Burke TV. Allergic rhinoconjunctivitis in elite athletes: optimal management for quality of life and performance. Sports Med 2003;33(6):401–6.
[19] McFadden Jr ER, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994;330(19):1362–7.
[20] Helenius I, Haataela T. Allergy and asthma in elite summer sport athletes. J Allergy Clin Immunol 2000;106(3):444–52.
[21] Gioulekas D, Damialis A, Papakosta D, et al. 15-year aeroallergen records. Their usefulness in Athens Olympics. 2004. Allergy 2003;58(9):933–8.
[22] Fitch KD. Management of allergic Olympic athletes. J Allergy Clin Immunol 1984;73:722–7.
[23] Katelaris CH, Carrozzi FM, Burke TV, Fitch KD. A springtime Olympics demands special consideration for allergic athletes. J Allergy Clin Immunol 2000;106(2):260–6.
[24] Nelson RJ, Demas GE, Klein SL. Seasonal patterns of stress, immune function, and disease. 1st edition. Cambridge, MA: Cambridge University Press; 2002.
[25] Tsitoura DC, Kim S, Dabbagh K, et al. Respiratory infection with influenza A virus interferes with the induction of tolerance to aeroallergens. J Immunol 2000;165(5):3484–91.
[26] Dahl ME, Dabbagh K, Liggitt D, et al. Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells. Nat Immunol 2004;5(3):337–43.
[27] Stephens R, Randolph DA, Huang G, et al. Antigen-nonspecific recruitment of Th2 cells to the lung as a mechanism for viral infection-induced allergic asthma. J Immunol 2002;169(10):5458–67.
[28] Bell IR, Jasnosi ML, Kagan J, et al. Depression and allergies: survey of a nonclinical population. Psychother Psychosom 1991;55(1):24–31.
[29] Helenius IJ, Tikkanen HO, Sama S, et al. Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. J Allergy Clin Immunol 1998;101(5):646–52.
[30] Hellbling A, Jenoure P, Muller U. [The incidence of hay fever in leading Swiss athletes]. Schweiz Med Wochenschr 1990;120(7):231–6 [German].
[31] Prieto L, Gutierrez V, Linana J, et al. Bronchoconstriction induced by inhaled adenosine 5′-monophosphate in subjects with allergic rhinitis. Eur Respir J 2001;17(1):64–70.
[32] Ramsdale EH, Morris MM, Roberts RS, et al. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 1985;75(5):573–7.
[33] Berger WE. Treatment update: allergic rhinitis. Allergy Asthma Proc 2001;22(4):191–8.
[34] Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003;112(6):1021–31.
[35] Dykewicz MS. 7. Rhinitis and sinusitis. J Allergy Clin Immunol 2003;111(Suppl 2):S520–9.
[36] Richerson HB, Seebohm PM. Nasal airway response to exercise. J Allergy 1968;41(5):269–84.
[37] Hurwitz EL, Morgenstern H. Cross-sectional associations of asthma, hay fever, and other
allergies with major depression and low-back pain among adults aged 20–39 years in the United States. Am J Epidemiol 1999;150(10):1107–16.

[38] Addolorato G, Ancona C, Capristo E, et al. State and trait anxiety in women affected by allergic and vasomotor rhinitis. J Psychosom Res 1999;46(3):283–9.

[39] Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58(5):445–52.

[40] Schwartz LB. Mediators of human mast cells and human mast cell subsets. Ann Allergy 1987;58(4):226–35.

[41] Schwartz LB, Bradford TR, Irani AM, et al. The major enzymes of human mast cell secretory granules. Am Rev Respir Dis 1987;135(5):1186–9.

[42] Pollmacher T, Haack M, Schuld A, et al. Low levels of circulating inflammatory cytokines–do they affect human brain functions? Brain Behav Immun 2002;16(5):525–32.

[43] Turnbull AV, Rivier C. Regulation of the HPA axis by cytokines. Brain Behav Immun 1995;9(4):253–75.

[44] Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002;7(3):254–75.

[45] Goehler LE, Gaykema RP, Hansen MK, et al. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci 2000;85(1–3):49–59.

[46] Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000;110(7):1189–93.

[47] Griffin JW, Hunter G, Ferguson D, et al. Physiologic effects of an external nasal dilator. Laryngoscope 1997;107(9):1235–8.

[48] Portugal LG, Mehta RH, Smith BE, et al. Objective assessment of the breathe-right device during exercise in adult males. Am J Rhinol 1997;11(5):393–7.

[49] Fraser AD. Doping control from a global and national perspective. Ther Drug Monit 2004;26(2):171–4.

[50] Chait LD. Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology (Berl) 1994;113(3–4):381–7.

[51] Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97(2):617–26.

[52] Montgomery LC, Deuster PA. Effects of antihistamine medications on exercise performance. Implications for sportspeople. Sports Med 1993;15(3):179–95.

[53] Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147–334.

[54] Wilken JA, Kane RL, Ellis AK, et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(4):375–85.

[55] Jen A, Baroody F, de Timeo M, et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105(4):732–8.

[56] Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy 2000;55(Suppl 62):S6–11.

[57] Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105(5):917–22.

[58] McFadden Jr ER. Exercise-induced airway obstruction. Clin Chest Med 1995;16(4):671–82.

[59] McFadden Jr ER, Ingram Jr RH. Exercise-induced airway obstruction. Annu Rev Physiol 1983;45:453–63.

[60] Pierson WE, Voy RO. Exercise-induced bronchospasm in the XXIII summer Olympic games. N Engl J Med Allergy Proc 1988;9(3):209–13.

[61] Randolph C. Exercise-induced asthma: update on pathophysiology, clinical diagnosis, and treatment. Curr Probl Pediatr 1997;27(2):53–77.

[62] Tan RA, Spector SL. Exercise-induced asthma: diagnosis and management. Ann Allergy Asthma Immunol 2002;89(3):226–35.
[63] Karjalainen J, Lindqvist A, Laitinen LA. Seasonal variability of exercise-induced asthma especially outdoors. Effect of birch pollen allergy. Clin Exp Allergy 1989;19(3):273–8.

[64] Tsai CL, Saidel GM, McFadden Jr ER, et al. Radial heat and water transport across the airway wall. J Appl Physiol 1990;69(1):222–31.

[65] Gilbert IA, Fouke JM, McFadden Jr ER. Heat and water flux in the intrathoracic airways and exercise-induced asthma. J Appl Physiol 1987;63(4):1681–91.

[66] McFadden Jr ER, Nelson JA, Skowronske ME, et al. Thermally induced asthma and airway drying. Am J Respir Crit Care Med 1999;160(1):221–6.

[67] Carlsen KH. Exercise induced asthma in children and adolescents and the relationship to sports. Pediatr Allergy Immunol 1998;9(4):173–80.

[68] Tan RA, Spector SL. Exercise-induced asthma. Sports Med 1998;25(1):1–6.

[69] Wallace JM, Stein S, Au J. Special problems of the asthmatic patient. Curr Opin Pulm Med 1997;3(1):72–9.

[70] Poppius H, Muittari A, Kreus KE, et al. Exercise asthma and disodium cromoglycate. Br Med J 1970;4(731):337–9.

[71] Jones RS, Buston MH, Wharton MJ. The effect of exercise on ventilatory function in the child with asthma. Br J Dis Chest 1962;56:78–86.

[72] Rupp NT, Brudno DS, Guill MF. The value of screening for risk of exercise-induced asthma in high school athletes. Ann Allergy 1993;70(4):339–42.

[73] Milgrom H, Taussig LM. Keeping children with exercise-induced asthma active. Pediatrics 1999;104(3):e38.

[74] Mehta H, Busse W. Prevalence of exercise-induced asthma in the athlete. In: Weiler JM, editor. Allergic and respiratory disease in sports medicine. New York: Marcel Dekker, Inc; 1997. p. 81–6.

[75] Hallstrand TS, Curtis JR, Koepsell TD, et al. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr 2002;141(3):343–8.

[76] McKenzie DC, McLuckie SL, Stirling DR. The protective effects of continuous and interval exercise in athletes with exercise-induced asthma. Med Sci Sports Exerc 1994;26(8):951–6.

[77] Carroll N, Sly P. Exercise training as an adjunct to asthma management? Thorax 1999;54(3):190–1.

[78] Latimer KM, O’Byrne PM, Morris MM, et al. Bronchoconstriction stimulated by airway cooling. Better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone. Am Rev Respir Dis 1983;128(3):440–3.

[79] Tullett WM, Tan KM, Wall RT, et al. Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma. Thorax 1985;40(1):41–4.

[80] Roberts JA, Thomson NC. Attenuation of exercise-induced asthma by pretreatment with nedocromil sodium and minocromil. Clin Allergy 1985;15(4):377–81.

[81] Bundgaard A, Buch D, Schmidt A, et al. Pretreatment of exercise-induced asthma in children using disodium cromoglicate and fenoterol inhalation powder. Eur J Respir Dis Suppl 1983;130:36–41.

[82] American Academy of Pediatrics: Section on Allergy and Immunology; Section on Diseases of the Chest. Exercise and the asthmatic child. Pediatrics 1989;84(2):392–3.

[83] Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992;67(8):1014–7.

[84] Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342(8875):833–7.

[85] Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91(2):154–9.

[86] Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184–90.

[87] Milgrom H, Fix Jr RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody, rhuMAB-E25 Study Group. N Engl J Med 1999;341(26):1966–73.

[88] Kaliner MA. Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 2004;4(3):237–44.